美諾華(603538.SH):非潑羅尼原料藥獲得歐洲CEP證書
格隆匯12月15日丨美諾華(603538.SH)公佈,近日,公司收到歐洲藥品質量管理局(“EDQM”)簽發的關於非潑羅尼(原料藥)的歐洲CEP證書(歐洲藥典適用性證書)。藥品適應症:用於驅殺犬、貓體表跳蚤和犬蝨。
氟蟲腈(原料藥)作為公司的重點產品之一,此次該藥品順利獲得CEP證書,顯示了歐洲規範市場對該原料藥的工藝及質量的認可,體現了公司優秀的工藝研發和質量管控能力。為公司進一步拓展國際市場,提供了競爭基礎和優勢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.